Effects of Digoxin in Modern Heart Failure Treatment

You may not qualify if:

• Already using Digoxin or having used it on the last 9 days (washout period).
• Persistent potassium below 3.2 mmol/L.
• Persistent hypercalcaemia or hypomagnesaemia.
• Sick sinus syndrome without pacemaker or Implantable cardioverter-defibrillators (ICD).
• Grade II-III AV block without a pacemaker or ICD.
• Wolff-Parkinson-White syndrome.
• Heart rate below 55 bpm at rest in sinus rhythm or below 70 bpm in AF in patients without CRT or cardiac physiologic pacing.
• Age < 18 years old.
• Hypersensitivity to Digoxin, other digitalis glycosides or to any of the excipients
• Pregnant or lactating women. Woman of childbearing potential who do not accept to use the methods of contraception suggested for the trial.
• New heart failure medication in the previous 6 months.
• Change in class I HF dose (ARNi, ACEi, ARB, beta-blockers, SGLT2 inhibitors or MRA) in the previous 3 months.
• Recent (<6 months): myocardial infarction, coronary revascularization, surgery or catheter intervention for valvular heart disease, stroke, or cerebral ischaemia, start of heart failure device therapy potentially improving left ventricular ejection fraction or HF symptoms (e.g. cardiac resynchronization therapy, cardiac contractility modulation, baroreflex activation therapy)
• Significant renal insufficiency (Glomerular filtration rate (GFR) ≤ 15mL/min) as evaluated by the Cockcroft-Gault formula.
• NTproBNP values < 125pg/mL.
• +2 more criteria